Cite
HARVARD Citation
Saji, S. et al. (2022). Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. Lancet oncology. 23 (5), pp. 636-649. [Online].